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Abstract 
Myc-associated zinc finger protein (MAZ), also 
known as serum amyloid A-activating factor 1 
(SAF1), Pur-1 or Zif87, is ubiquitously expressed in 
various tissues.  MAZ is a transcription factor with 
six Cys2His2-type zinc finger motifs at the carboxyl-
terminus that interact with a permutation of the 
GGGAGGG sequence motif present in GC-rich 
promoter regions of target genes, likely through 
DNA unfolding of G-quadruplex structures to 
modulate gene expressions. MAZ is also suggested 
to participate in transcription termination and 
polyadenylation. Deregulated expression of MAZ is 
reported to correlate with various tissue 
malignancies that include the breast, thyroid, 
hepatocellular and urothelial cancers. 
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Identity 
Other names 
PUR1 (Purine-Binding Transcription Factor), SAF-
1 (Serum Amyloid A Activating Factor 1), SAF-2 
(Serum Amyloid A Activating Factor 2), SAF-3 
(Serum Amyloid A Activating Factor 3), ZF87 
(Transcription Factor Zif87), ZNF801 (Zinc Finger 
Protein 801) 
HGNC (Hugo) 
MAZ 
Location 
16p11.2 
Location (base pair) 
chr16:29,817,858-29,822,504; 4,647 bp. 
UCSC representation of the gene on chromosome 16. RefSeq sequence shows introns as lines, exons as boxes 
and encoding exons as thicker boxes. Retrieved from: http://genome.ucsc.edu on November 6, 2017. 
DNA/RNA 
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The human MAZ consists of six exons, the first five of which are encoding exons; total exon length is 4.57 kb 
(Song et al., 1998). 
Description 
The human MAZ contains six exons; the encoding 
sequence consists of 1431 bases (Song et al., 1998). 
Transcription 
The human gene encoding for MAZ is located on 
chromosome 16p11.2 and is transcribed as an 
mRNA of 2.7 kilobases (kb). The primary transcript 
encodes a 477 amino-acid long MAZ-1 protein with 
a 60-kDa molecular mass that contains six C2H2-
type zinc-finger domains responsible for DNA 
binding. MAZ protein has two additional isoforms: 
MAZ-2 and MAZ-3. The MAZ-2 transcript is 
generated by an alternative splicing that results in the 
insertion of a new exon originating from the non-
coding sequences of the intron 4. This transcript 
gives rise to the MAZ-2 isoform, which is a 493 
amino-acids long protein with distinct carboxyl-
terminus which contains two additional zinc-finger 
domains (Ray et al., 2002). The MAZ-2 isoform is 
reported to have a higher DNA-binding activity and 
to act as a negative regulator of MAZ-1 function 
(Ray et al., 2002). The MAZ-3 transcript is 
expressed at very low levels under normal 
physiological condition in various tissues, but is 
highly expressed during inflammation. The MAZ-3 
transcript is transcribed from a distinct upstream 
promoter and is processed with alternative splicing. 
The MAZ-3 transcript is translated from a different 
starting codon that gives rise to the MAZ-3 isoform 
of 455 amino-acids (Ray et al., 2009). 
Pseudogene 
No reported pseudogenes are found. 
Protein 
 
Domains of MAZ are depicted with vertical colored lines; Blacks are Poly-Alanine repeats; Green is Poly-
Proline tract; Red column is Poly-Glycine repeat. C2H2-type zinc finger domains of MAZ-1 are represented in 
dark blue-green vertical lines 
 
. 
Description 
The human MAZ protein contains three Poly 
alanine, one poly-proline and one poly-glycine 
domains (Song et al., 1998). Poly-alanine repeats 
considered to have role in cellular localization of the 
protein; the alteration in the intracellular distribution 
may contribute to diseases, including muscular 
dystrophy (OPMD) (Oma et al., 2004). Similarly, 
poly-glycine repeats are responsible in protein 
targeting (Uthayakumar et al., 2012). Poly-proline 
tracks, on the other hand, generates structures that 
are predicted to have important roles in protein-
protein interactions (Williamson, 1994). The human 
MAZ-1 contains six C2H2-type zinc finger domains 
(Song et al., 1998), which are frequently occurring 
in proteins involved in transcriptional regulation. 
MAZ (MYC Associated Zinc Finger Protein)  
 
Atlas Genet Cytogenet Oncol Haematol. 2018; 22(8) 325 
 
 
Expression and synthesis of MAZ in various cancerous tissues. Retrieved from: 
http://www.proteinatlas.org/ENSG00000103495-MAZ/cancer on November 2, 2017. 
 
Expression 
MAZ is expressed in the human heart, brain, lungs, 
liver, skeletal muscle, pancreas, and prostate (Jiao et 
al., 2013; Dudas et al., 2008). The synthesis of MAZ 
protein is observed to occur at high levels in breast, 
thyroid and urothelial cancers as well as in 
melanoma (Ugai et al., 2001) 
 
Immunofluorescent staining of human cell line MCF7. Retrieved from: 
http://www.proteinatlas.org/ENSG00000103495-MAZ/cell on November 2, 2017. Immunofluorescent staining 
of MCF7 cells derived from breast adenocarcinoma shows that MAZ localizes to the nucleus. 
 
Localisation 
MAZ is located in the nucleus (Jordan-Sciutto et al, 
2000). 
Function 
MAZ as a transcription factor interacts with a 
permutation of the GGGAGGG sequence motif 
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present in GC-rich promoter regions of target genes 
by unfolding of G-quadruplex structures of DNA 
(Cogoi et al., 2014) to activate or repress 
transcription. MAZ is also suggested to participate in 
transcription termination and polyadenylation. 
Several oncogenes, including MYC, HRAS, 
PPARG, TSG101, VEGFA, CAV1, PTHR1, NOS3, 
MYB, and hTER, are transcriptionally regulated by 
MAZ (Jun Song et al., 2001; Lee et al., 2016; Ray et 
al., 2002). Deregulated expression of MAZ appears 
to participate in the development and/or progress 
various tissue malignancies including the breast, 
thyroid, hepatocellular and urothelial cancers (Jiao et 
al., 2013; Dudas et al., 2008; Yu et al., 2017; Ray, 
2011; Zhu et al., 2016) 
Homology 
The human MAZ protein is conserved 100% in 
chimpanzee (P.troglodytes), 98.4% in mouse 
(M.musculus), and 98.4% in rat (R.norvegicus); with 
conserved DNA of 99.8%, 93.2%, and 92.7%, 
respectively (Retrieved from: 
https://blast.ncbi.nlm.nih.gov/Blast.cgi. November 
2, 2017). 
Mutations 
Note 
Genetic mutations are not described for MAZ. 
Implicated in 
Prostate cancer 
It was reported that the MAZ expression is higher in 
clinical prostate cancer (PCa) specimens than in 
benign prostatic hyperplasia (BPH) and adjacent 
normal tissues (Jiao et al., 2013). Moreover, the 
MAZ expression appears to be positively correlated 
with the expression of androgen receptor ( AR), 
which is critical for the initiation and development 
of androgen-dependent PCa (Jiao et al., 2013). 
Extending these findings, experimental studies in 
cell models derived from PCa indicated that MAZ is 
involved in the phenotypic manifestation of PCa cell 
models as siRNA knockdown of MAZ levels 
reduces cell proliferation, migration, and invasion 
through mechanisms involve the expression of AR 
(Jiao et al., 2013). 
Hepatocellular carcinoma 
The expression of MAZ was reported to be 
upregulated in the majority (78.94%) of 
hepatocellular carcinoma (HCC) samples compared 
to normal liver samples (Dudas et al., 2008). 
Experimental studies using cell lines derived from 
HCC further suggest that MAZ-mediated regulation 
of PROX1, which is a transcription factor critical for 
the expression of a number of genes involved in 
hepatic metabolic functions, contributes to the 
progression of HCC (Dudas et al., 2008). 
Breast cancer 
Based on data sets in Gene expression-based 
Outcome for Breast Cancer Online (GOBO, 
http://co.bmc.lu.se/gobo/), the expression of MAZ is 
found to be correlated with distant metastasis-free 
survival (DMFS) in basal-like breast cancer (BLBC) 
patients and that the under-expression of MAZ is 
involved in the metastatic spread of BLBC (Yu et al., 
2017). Based on these finding, it was suggested that 
MAZ plays dual roles in basal-like breast cancer 
(BLBC): it suppresses cancer progression but 
promotes cellular proliferation (Yu et al., 2017). 
Experimental studies using model cell lines derived 
from breast cancer indeed suggest that MAZ 
promotes cell proliferation yet it suppresses the 
aggressiveness of BLBC by controlling the transition 
toward a more mesenchymal phenotype (Yu et al., 
2017; Ray, 2011). 
Pancreatic carcinoma 
Based on samples from pancreatic carcinoma 
patients, it was reported that the expression of MAZ 
is significantly higher in PC tissue compared to the 
adjacent non-tumor tissues (Zhu et al., 2016). 
Moreover, it appears that the over-expression of 
MAZ is associated with poor prognosis of PC 
patients (Zhu et al., 2016). 
Hodgkin's Disease and 
Paraneoplastic Cerebellar 
Dysfunction 
In neuronal cells, MAZ interacts with the Deleted in 
Colorectal Cancer product ( DCC), the receptor for 
NTN1 netrin-1 which plays a central role in axonal 
guidance and neuronal migration as well as survival 
during development. Analyses of sera from patients 
with HD and PCD Hodgkin's disease and 
paraneoplastic cerebellar degeneration indicated that 
patient sera contain auto-antigens directed against 
the MAZ-DCC complex.  Based on these 
observations, it was speculated that auto-antigens 
could interfere with neuronal function resulting in 
neuronal degeneration (Bataller and Wade, 2002). 
To be noted 
Expression of the MAZ gene is found to be regulated 
by MIR-125B, which is suggested to affect VEGF-
induced angiogenesis in glioblastoma (Vandertop et 
al., 2017).  
 
MIR449A targets MAZ transcripts, the down-
regulation of which is reported to contribute to 
glioblastoma (Chen et al., 2015; Zhao et al., 2014; 
Yao et al., 2015).  
 
MIR34C is also reported to target MAZ. Decrease 
levels of MAZ by miR-34c are suggested to impair 
the integrity and increased the permeability of blood-
tumor barrier (Zhao et al., 2014). 
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